Wednesday, 30 January 2013

Mesoblast commences Phase 2 stem cell clinical trials on Rheumatoid Arthritis

Mesoblast announced yesterday that it has received approval from the FDA to initiate Phase 2 human clinical trials for Rheumatoid Arthritis. The trial will test the efficacy and safety of their mesenchymal stem cell product for RA. It is worth mentioning that 20 days ago, Mesoblast also announced positive clinical trial results on an other stem cell product they own, Neofuse.

According to the announcement, the clinical trial is expected to start sometime after May 2013. The study will be placebo controlled and will test the efficiency and safety of a single intravenous infusion of  mesenchymal progenitor cells (MPC) in patients with poor response to biologic inhibitors of the TNF-alpha pathway. The trial will be conducted in the U.S., Australia and Europe.

Previous preclinical animal studies have shown that the company's MPC therapy resulted in great reduction of inflammation and autoimmune response.

Image showing a severy affected hand by RA
Hand affected by rheumatoid arthritis

If you are interested to enrol please call 61 (0) 3 9639 6036

Rheumatoid Arthritis is a long term autoimmune disease that leads to inflammation of the joints and surrounding tissues.The exact causes of the condition remain largely unknown. The condition is the result of the body's immune system mistakenly attacking  healthy tissue and cells. Around 1 % of the total population is affected by the condition, with women being more prone to it. 

A rheumatologist talks about RA

You can download the company's official announcement here

No comments:

Post a Comment

Please note that we dont offer any kind of medical advice. Questions requesting specific medical advice (e.g. where can I get this treatment, will this cure XXX condition, etc) will be published but most probably ignored by the administrators. :)

Note to spammers: You shall not pass. If you really want a link from us then consider making a stem cell related guest post !